Novartis’ radioligand therapy granted US Breakthrough Therapy Designation
Lu-PSMA-617 is a potential treatment for metastatic castration-resistant prostate cancer
Read More
Tag: radioligand therapy
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
